Intraocular Melanoma
Conditions
Keywords
ciliary body and choroid melanoma, medium/large size, extraocular extension melanoma, iris melanoma, epithelioid cell intraocular melanoma, stage IIB intraocular melanoma, stage IIIA intraocular melanoma, stage IIIB intraocular melanoma, stage IIIC intraocular melanoma, stage IV intraocular melanoma
Brief summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as tamoxifen and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib together with tamoxifen and cisplatin may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving sunitinib together with tamoxifen and cisplatin works in treating patients with high-risk ocular melanoma.
Detailed description
OBJECTIVES: * Determine the effect of adjuvant sunitinib malate, tamoxifen citrate, and cisplatin on disease-free survival and overall survival of patients with high-risk ocular melanoma who have undergone primary therapy. * Determine the toxicity of this regimen in these patients. OUTLINE: This is a pilot study. Patients receive oral sunitinib malate once daily on days 1-21, oral tamoxifen citrate twice daily on days 1-7, and cisplatin IV on days 2 and 3. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 2 months for 2 years.
Interventions
DRUGcisplatin
DRUGsunitinib malate
DRUGtamoxifen citrate
PROCEDUREadjuvant therapy
Sponsors
San Diego Pacific Oncology & Hematology Associates
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of ocular melanoma * High-risk disease, defined by any of the following: * Large choroidal tumors with a basal diameter ≥ 16 mm and/or tumor thickness ≥ 10 mm (T3) * Extrascleral extension (T4) * Ciliary body involvement * Epithelioid cell type only * Have undergone appropriate primary treatment for ocular melanoma * No measurable metastatic disease PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * ANC ≥ 1,200/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9.0 g/dL * Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min * AST and ALT ≤ 3 times upper limit of normal * Pancreatic enzymes normal * Thyroid function normal or stable on replacement therapy * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Cardiac ejection fraction ≥ 50% by MUGA or ECHO * No myocardial infarction within the past 6 months * No congestive heart failure requiring medication * No history of pulmonary disease requiring supplemental oxygen * No dyspnea at rest * No active infection * No chronic underlying immunodeficiency disease * No other serious illness that would preclude patient safety, in the opinion of the investigator * No other cancer within the past 5 years except nonmelanoma skin cancer or cervical cancer * No thromboembolic disease within the past 6 months PRIOR CONCURRENT THERAPY: * No prior sunitinib malate, tamoxifen citrate, or cisplatin * No other concurrent chemotherapy, radiotherapy, or surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival | — |
| Overall survival | — |
| Toxicity | — |
Countries
United States
Outcome results
None listed